Zonalta 8mg Tablet contains Endoxifen 8mg, an active metabolite of tamoxifen, primarily used in the management of hormone receptor-positive breast cancer. Endoxifen functions as a selective estrogen receptor modulator (SERM), exerting anti-estrogenic effects by competitively binding to estrogen receptors, thereby inhibiting estrogen-mediated cellular proliferation in breast tissue. This mechanism is particularly beneficial in reducing the risk of cancer recurrence and progression in patients with estrogen receptor-positive tumors. Zonalta is indicated for adjuvant therapy in early-stage breast cancer as well as for the treatment of metastatic breast cancer in both premenopausal and postmenopausal women. The tablet is administered orally, with dosage and duration tailored according to clinical response and physician guidance. Common adverse effects may include hot flashes, nausea, fatigue, and mild gastrointestinal disturbances; however, serious side effects such as thromboembolic events and endometrial changes require close monitoring. Patients with a history of thromboembolic disorders or hypersensitivity to the drug should use Zonalta cautiously. Regular follow-up and assessment of liver function and ocular health are recommended during therapy. Zonalta 8mg Tablet offers a targeted therapeutic option in hormone-responsive breast cancer management, enhancing patient outcomes through its estrogen receptor antagonism.